-
Depositing Lab
-
Publication
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 25038 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepMIR-report
-
Backbone manufacturerAmbion
- Backbone size w/o insert (bp) 6470
-
Vector typeMammalian Expression, Luciferase
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCDH1 3'UTR
-
Alt nameCDH1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)819
-
Entrez GeneCDH1 (a.k.a. Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM, UVO)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site SpeI (unknown if destroyed)
- 3′ cloning site HindIII (unknown if destroyed)
- 5′ sequencing primer Luc-F
- 3′ sequencing primer M13/pUC Forward (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
A partial CDH1 3'UTR (819bp) was PCR-amplified from normal human genomic DNA and cloned into the pMIR-report vector.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pMIR-CDH1 wtUTR was a gift from Bob Weinberg (Addgene plasmid # 25038 ; http://n2t.net/addgene:25038 ; RRID:Addgene_25038) -
For your References section:
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. Nat Cell Biol. 2010 Mar . 12(3):247-56. 10.1038/ncb2024 PubMed 20173740